Evaluation of FOXC1 as a therapeutic target for basal-like breast cancer

Biochemistry, Genetics and Molecular Biology

• Growth 100%
• Phenotype 50%
• Transcription Factor 50%
• Cancer Cell 50%
• CRISPR/Cas9 50%
• Small Interfering RNA 50%
• Relapse 50%
• Tumor Volume 50%